Next Science (ASX:NXS) Common Stock: A$205.71 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NXS Next Science Ltd ASX:NXS
25 GF Score
Price A$0.15
GF Value A$37.70
! 7 Warning Signs
View Full Analysis

What is Next Science Common Stock?

Next Science ASX:NXS 25 Common Stock is A$205.71 Mil as of Jun. 2025. GuruFocus rates ASX:NXS with a GF Score™ of 25/100 and a GF Value™ of A$37.70. The stock has 7 warning signs investors should review.

Next Science's quarterly common stock increased from Jun. 2024 (A$201.54 Mil) to Dec. 2024 (A$211.47 Mil) but then declined from Dec. 2024 (A$211.47 Mil) to Jun. 2025 (A$205.71 Mil).

Next Science's annual common stock increased from Dec. 2022 (A$168.25 Mil) to Dec. 2023 (A$199.93 Mil) and increased from Dec. 2023 (A$199.93 Mil) to Dec. 2024 (A$211.47 Mil).

Next Science Common Stock Historical Data

* Premium members only.

The historical data trend for Next Science's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science Common Stock Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial 134.50 143.88 168.25 199.93 211.47

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 169.16 199.93 201.54 211.47 205.71
ASX:NXS
25GF Score
Next Science Ltd ASX:NXS
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Next Science Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$205.71 Mil mean?
Next Science (ASX:NXS) has a Common Stock of A$205.71 Mil as of Jun. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Next Science and its competitors.
Is Next Science's Common Stock too high?
Next Science's current Common Stock is A$205.71 Mil. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's Common Stock compare to GCAN and PTPI?
Next Science's Common Stock of A$205.71 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Next Science and its competitors. Next Science's current Common Stock is A$205.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current Common Stock of A$205.71 Mil. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current Common Stock is A$205.71 Mil. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Next Science (ASX:NXS), the current Common Stock is A$205.71 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Next Science (ASX:NXS) Overvalued in 2026?

Based on GuruFocus' analysis, Next Science stock appears to be undervalued. The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.

Key valuation signals for ASX:NXS:

  • Common Stock: A$205.71 Mil
  • GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Next Science Business Description

Address 264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score

Get the complete analysis for ASX:NXS

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price
A$37.70
GF Value